This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pearson, J. D. Search for Related Content PubMed PubMed Citation Articles by Pearson, J. D. Related Collections Developmental biology Coagulation Other Vascular biology

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:2117.)
© 2003 American Heart Association, Inc.

Editorials

Using Endothelial Progenitor Cells for Gene Therapy

Jeremy D. Pearson

From the Center for Cardiovascular Biology and Medicine, King’s College London, UK.

Correspondence to Jeremy D. Pearson, Center for Cardiovascular Biology and Medicine, King’s College London, Guy’s Campus, London SE1 1UL, UK E-mail jeremy.pearson@kcl.ac.uk

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Readers of Arteriosclerosis, Thrombosis, and Vascular Biology are already well aware of the high level of interest in gene therapy as a potential means of combating cardiac and vascular disease. During the last 10 years or so there have been clear demonstrations in a variety of animal models that it is possible to modulate the progress of atherosclerotic vascular disease, restenotic arterial disease, or venous graft disease by transgenic or knockout approaches. These studies have concomitantly generated a series of experiments in which local gene therapy, predominantly using adenoviral vectors, has been used to attempt to ameliorate restenosis in grafts or after vascular injury and to enhance angiogenesis in and around areas of ischemic or infarcted tissue. The essential vision of successful human gene therapy for cardiovascular diseases remains undimmed,¹ but the original enthusiastic optimism has been tempered by reality: there are significant generic problems such as inflammatory side effects due to the current generation of viral vectors and potential safety concerns for long-term gene therapy highlighted by the cases of leukemia in children being treated for immunodeficiency diseases² in addition to the complications inherent in trying to treat complex disease processes with a single magic bullet. Nonetheless, several uncontrolled clinical trials, but very few controlled trials so far, have suggested benefit from local transfer of the gene for vascular endothelial growth factor into the heart after myocardial infarction or into the leg to overcome peripheral ischemia.^3,4

See page 2266

While the significant hurdles that need to be overcome to . . . [Full Text of this Article]

This article has been cited by other articles:

				R. C.M. Siow and A. T. Churchman Adventitial growth factor signalling and vascular remodelling: Potential of perivascular gene transfer from the outside-in Cardiovasc Res, September 1, 2007; 75(4): 659 - 668. [Abstract] [Full Text] [PDF]